Patient


  • J&J HQ
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Inside J&J’s strategy to de-gender clinical trials

    Mark Wildgust, vice president of global medical affairs for J&J's oncology division, shares strategies for making clinical trials gender- and trans-inclusive.

    By Alexandra Pecci • April 23, 2024
  • A photograph of a box of Amylyx Pharmaceuticals' ALS medicine Relyvrio
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Behind the ‘encouraging’ new results for Amylyx’s beleaguered drug

    Where Amylyx ultimately failed in ALS, it could prevail in a rare disease. The doctor leading this research explains why.

    By April 19, 2024
  • test tube gene Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Cell and gene therapies

    How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

    By PharmaMore staff
  • Damaged hospital Ukraine
    Image attribution tooltip
    Chris McGrath via Getty Images
    Image attribution tooltip
    Deep Dive

    Ukraine was pharma’s ‘darling’ of clinical trials. As war drags on, will the industry come back?

    New clinical trial starts are picking back up, but are still far below their bustling pre-war level.

    By April 16, 2024
  • glp-1 injector
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Where the GLP-1 weight loss market goes will depend on data

    As GLP-1s expand into new disease categories, their impact could be enough to overtake leading cardiovascular drugs.

    By April 15, 2024
  • broken syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 big recent trial flops

    How these clinical setbacks impacted the companies, industry and patients.

    By April 12, 2024
  • A person wearing a white coat works at a research laboratory bench.
    Image attribution tooltip
    Permission granted by Bristol Myers Squibb
    Image attribution tooltip
    Deep Dive

    Psychiatry drugs finally have pharma’s attention. Can they keep it?

    Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.

    By Jacob Bell • April 10, 2024
  • mpox hands
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Viral return: 3 U.S. cases concerning experts

    Infectious diseases that were “off the playing field” are now making a comeback.

    By April 5, 2024
  • Bernice Bennett, genealogist
    Image attribution tooltip
    Permission granted by Alnylam
    Image attribution tooltip

    Alnylam turns to genealogy to find rare disease patients through family trees

    A vastly underdiagnosed rare disease presents a challenge to Alnylam’s commercial team, but a family health road trip has patients talking about their hereditary risk.

    By March 26, 2024
  • Debra Weiss
    Image attribution tooltip
    Permission granted by Gates MRI
    Image attribution tooltip
    Profile

    The pharma ‘fixer’ now helping Gates MRI’s tuberculosis battle

    After getting her start as a nurse, Debra Weiss worked her way up the corporate ladder and is now COO of Gates MRI, which just launched its first phase 3 trial for tuberculosis.

    By Alexandra Pecci • March 22, 2024
  • Colorful DNA double helix.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Orchard sets out to sell world’s priciest gene therapy

    Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25 million list price, the highest of any genetic medicine to come to market.

    By Kristin Jensen • March 20, 2024
  • brain pills
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    After Amylyx drug failure, what’s next for ALS?

    The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.

    By March 15, 2024
  • U.S. President Joe Biden
    Image attribution tooltip
    Alex Wong/Getty Images via Getty Images
    Image attribution tooltip
    Q&A

    Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake

    A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.

    By March 14, 2024
  • liquid biopsy
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients

    As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.

    By Alexandra Pecci • March 12, 2024
  • Doctor checking patient's lymph nodes under their jaw in a medical office.
    Image attribution tooltip

    Adobe Stock / LuneVA/peopleimages.com

    Image attribution tooltip
    Sponsored by MMIT

    Why pharma should prioritize the patient journey: A survivor’s story

    One rare disease survivor’s diagnosis experience highlights the need for pharma companies to better understand the patient journey.

    By Carolyn Zele, Solution Consulting Advisor, MMIT • March 11, 2024
  • Bobak Azamian horizontal no logo
    Image attribution tooltip
    Permission granted by Tarsus Pharmaceuticals
    Image attribution tooltip
    Q&A

    Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category

    The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.

    By March 8, 2024
  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx ALS drug fails crucial study, putting company’s future in doubt

    The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

    By Jacob Bell • Updated March 8, 2024
  • exterior of the supreme court
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    Could pharma’s legal attack on the IRA succeed in killing price negotiations?

    An all-out blitz across U.S. courts is bolstering pharma’s goal to overturn Medicare drug price negotiations.

    By March 6, 2024
  • Dr. Marc Conant, chief medical officer, American Gene Technologies
    Image attribution tooltip
    Permission granted by Natalie Ferguson/American Gene Technologies
    Image attribution tooltip
    Profile

    HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure

    From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.

    By March 5, 2024
  • House Energy And Commerce Committee Chair Cathy Rodgers stern look
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    After ‘tragic’ bacterial outbreak, lawmakers press FDA to step up foreign inspections

    Impatience to fix long-held challenges to overseas drug facility inspections is growing on Capitol Hill.

    By March 1, 2024
  • Gianluca Pirozzi header
    Image attribution tooltip
    Permission granted by Gianluca Pirozzi
    Image attribution tooltip
    Profile

    Behind a big-name rare disease biotech, an exec draws from personal experience

    The personal impact of rare disease has shaped Gianluca Pirozzi, a senior vice president at AstraZeneca’s Alexion, as a parent and drug developer.

    By Alexandra Pecci • Feb. 27, 2024
  • Iovance hallway
    Image attribution tooltip
    Permission granted by Iovance Biotherapeutics
    Image attribution tooltip

    Behind the breakthrough cancer therapy that just won a historic FDA nod

    The first-of-its-kind TIL therapy for solid tumors developed by Iovance Biotherapeutics won FDA approval last week.

    By Kelly Bilodeau • Feb. 21, 2024
  • One of Kite Pharma's buildings.
    Image attribution tooltip
    Courtesy of Kite Pharma, Inc.
    Image attribution tooltip

    Kite’s next-gen CAR-T aims include quicker production and more disease targets

    While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.

    By Kelly Bilodeau • Feb. 20, 2024
  • pill loading
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    ‘Hey, AI: Is Zoloft effective for me?’ Tech’s foray into predictive prescribing

    Researchers are unleashing the powers of AI for precision medicine, drug development and more.

    By Alexandra Pecci • Feb. 15, 2024
  • Niesha Foster, Pfizer
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip

    ‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity

    The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.

    By Feb. 14, 2024
  • Drug pill question
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    These 4 drugs had tons of promise — and they flopped. What happened?

    No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.

    By Alexandra Pecci • Feb. 13, 2024